



Methyl-Containing Pharmaceuticals

Guest Editors:

Dr. Anna Fantinati

Dept. Department of
Environmental and Prevention
Sciences – DEPS, University of
Ferrara, Via Fossato di Mortara
17, 44121 Ferrara, Italy

Dr. Davide Illuminati

Dept. of Chemical,
Pharmaceutical and Agricultural
Sciences – DOCPAS, University of
Ferrara, Via Fossato di Mortara
17, 44121 Ferrara, Italy

Deadline for manuscript
submissions:

closed (29 December 2023)

Message from the Guest Editors

Dear Colleagues,

For this Special Issue, we will consider manuscripts focused on any type of target involved in pharmaceutical methyl-containing profiles, from peptides to anti-fungal/anti-tumoral targets, considering a broad spectrum of applications. For example, there are pharmaceuticals targeting GPCRs (multiple G protein-coupled receptors), GPCRs mediate most of our physiological responses to hormones, neurotransmitters and environmental stimulants, and so they have potential as therapeutic targets for a broad spectrum of diseases. Even the smallest modification of a molecule can lead to the discovery of an important therapeutic effect. The methyl effect is well acknowledged in medicinal chemistry; the insertion of the smallest alkyl group could have important implications in modulating the biological activity, selectivity, metabolism and pharmacokinetic/pharmacodynamic properties of the bioactive molecules already highlighted. The purpose of this Special Issue is to combine synthetic strategies to methylate potential drug profiles with the identification of pharmaceuticals through significant lead optimization processes to create new biologically active compounds.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e
Bioquímica (DQB) e Centro de
Química Estrutural (CQE),
Institute of Molecular Sciences,
Faculdade de Ciências,
Universidade de Lisboa, Lisboa,
Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Contact Us

Pharmaceuticals Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com
[X@Pharmaceut_MDPI](#)